Role of a LIF antagonist in LIF and OSM induced MMP-1, MMP-3, and TIMP-1 expression by primary articular chondrocytes

Cytokine

Volumn 46, Issue 3, 2009, Pages 332-338

  Upadhyay, Aradhana ^a   Sharma, Gaurav ^a   Kivivuori, Satu ^b   Raye, Warren S ^a   Zabihi, Ebrahim ^d   Carroll, Graeme J ^c   Jazayeri, Jalal A ^a  

^a MONASH UNIVERSITY   (Australia)

^b Smerud Medical Research Finland AB/Oy   (Finland)

^c FREMANTLE HOSPITAL   (Australia)

^d BABOL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cartilage; Leukemia inhibitory factor (LIF); Matrix metalloproteinases (MMPs); Oncostatin M (OSM)

Indexed keywords

CYTOKINE; GROWTH FACTOR; HYBRID PROTEIN MH35 BD; INTERSTITIAL COLLAGENASE; LEUKEMIA INHIBITORY FACTOR RECEPTOR; LIF RECEPTOR ANTAGONIST; MH35 BD; ONCOSTATIN M; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CARTILAGE CELL; CARTILAGE DEGENERATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; METACARPOPHALANGEAL JOINT; NONHUMAN; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SWINE; SYNOVIAL FLUID; TRANSCRIPTION REGULATION;

ANIMALS; CARTILAGE, ARTICULAR; CHONDROCYTES; HUMANS; LEUKEMIA INHIBITORY FACTOR; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 3; ONCOSTATIN M; RECOMBINANT PROTEINS; SWINE; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

SUS;

EID: 67349235017     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2009.03.001     Document Type: Article

References (49)

1. Cawston T. Matrix metalloproteinases and TIMPS: properties and implications for the rheumatic diseases. Mol Med Today March (1998) 130-137
2. Abeles A.M., and Pillinger M.H. The role of the synovial fibroblast in rheumatoid arthritis-cartilage destruction and the regulation of matrix metalloproteinases. Bull Hosp Jt Dis 64 (2006) 20-24
3. Christoper J. Nile RCRMAGWDAGW. Methylation status of a single CpG site in the IL6 promoter is related to IL6 messenger RNA levels and rheumatoid arthritis. Arthritis Rheum 58 (2008) 2686-2693
4. Yoshihara Y., Nakamura H., Obata K., Yamada H., Hayakawa T., Fujikawa K., et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 59 (2000) 455-461
5. Rose K., Davidson R., Waters J., Kevorkian L., Darrah C., Cooper A., et al. Expression profiling of metalloproteinases and their inhibitors in synovium and cartilage. Arthritis Res Ther 8 (2006) R124
6. Davidson R.K., Waters J.G., Kevorkian L., Darrah C., Cooper A., Donell S.T., et al. Expression profiling of metalloproteinases and their inhibitors in synovium and cartilage. Arthritis Res Ther 8 (2006) R124
7. Muller-Ladner U., and Gay S. MMPs and rheumatoid synovial fibroblasts: siamese twins in joint destruction?. Ann Rheum Dis 61 (2002) 957-959
8. Kevorkian L., Young D., Darrah C., Donell S.T., Shepstone L., Porter S., et al. Expression profiling of metalloproteinases and their inhibitors in cartilage. Arthritis Rheum 50 (2004) 131-141
9. Migita K., Eguchi K., Kawabe Y., Ichinose Y., Tsukada T., Aoyagi T., et al. TNF-alpha-mediated expression of membrane-type matrix metalloproteinase in rheumatoid synovial fibroblasts. Immunology 89 (1996) 553-557
10. Hembry R.M., Bagga M.R., Dingle J.T., Thomas P.P., and Reynolds J.J. Metalloproteinase production by rabbit articular cartilage: comparison of the effects of interleukin-1 alpha in vitro and in vivo. Virchows Arch 425 (1994) 413-424
11. Langdon C., Kerr C., Hassen M., Hara T., Arsenault A.L., and Richards C.D. Murine oncostatin M stimulates mouse synovial fibroblasts in vitro and induces inflammation and destruction in mouse joints in vivo. Am J Pathol 157 (2000) 1187-1196
12. Li W.Q., Dehnade F., and Zafarullah M. Oncostatin M-induced matrix metalloproteinase and tissue inhibitor of metalloproteinase-3 genes expression in chondrocytes requires Janus kinase/STAT signaling pathway. J Immunol 166 (2001) 3491-3498
13. Gatsios P., Haubeck H.D., Van de Leur E., Frisch W., Apte S.S., Greiling H., et al. Oncostatin M differentially regulates tissue inhibitors of metalloproteinases TIMP-1 and TIMP-3 gene expression in human synovial lining cells. Eur J Biochem 241 (1996) 56-63
14. Benigni F., Fantuzzi G., Sacco S., Sironi M., Pozzi P., Dinarello C.A., et al. Six different cytokines that share GP130 as a receptor subunit, induce serum amyloid A and potentiate the induction of interleukin-6 and the activation of the hypothalamus-pituitary-adrenal axis by interleukin-1. Blood 87 (1996) 1851-1854
15. Heymann D., L'Her E., NG J.M., Raher S., Canfrere I., Coupey L., et al. Leukaemia inhibitory factor (LIF) production in pleural effusions: comparison with production of IL-4, IL-8, IL-10 and macrophage-colony stimulating factor (M-CSF). Cytokine 8 (1996) 410-416
16. Gearing D.P., Comeau M.R., Friend D.J., Gimpel S.D., Thut C.J., McGourty J., et al. The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor. Science 255 (1992) 1434-1437
17. Desgeorges A., Gabay C., Silacci P., Novick D., Roux-Lombard P., Grau G., et al. Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. J Rheumatol 24 (1997) 1510-1516
18. Morgan T.G., Rowan A.D., Dickinson S.C., Jones D., Hollander A.P., Deehan D., et al. Human nasal cartilage responds to oncostatin M in combination with interleukin 1 or tumour necrosis factor alpha by the release of collagen fragments via collagenases. Ann Rheum Dis 65 (2006) 184-190
19. Ernst M., Inglese M., Waring P., Campbell I.K., Bao S., Clay F.J., et al. Defective gp130-mediated signal transducer and activator of transcription (STAT) signaling results in degenerative joint disease, gastrointestinal ulceration, and failure of uterine implantation. J Exp Med 194 (2001) 189-203
20. Hui W., Bell M., Carroll G., and Layton M.J. Modulation of cartilage proteoglycan metabolism by LIF binding protein. Cytokine 10 (1998) 220-226
21. Lotz M., Moats T., and Villiger P.M. Leukemia inhibitory factor is expressed in cartilage and synovium and can contribute to the pathogenesis of arthritis. J Clin Invest 90 (1992) 888-896
22. Carroll G., Bell M., and Hui W. Role of oncostatin M in the regulation of cartilage macromolecule metabolism: comment on the article by Nemoto et al. Arthritis Rheum 40 (1997) 589-590
23. Hui W., Rowan A.D., Richards C.D., and Cawston T.E. Oncostatin M in combination with tumor necrosis factor α induces cartilage damage and matrix metalloproteinase expression in vitro and in vivo. Arthritis Rheum 48 (2003) 3404-3418
24. Fairlie W.D., Uboldi A.D., McCoubrie J.E., Wang C.C., Lee E.F., Yao S., et al. Affinity maturation of leukemia inhibitory factor and conversion to potent antagonists of signaling. J Biol Chem 279 (2004) 2125-2134
25. Smith D.B., and Johnson K.S. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene 67 (1988) 31-40
26. Zhang Y., Willson T., Metcalf D., Cary D., Hilton D.J., Clark R., et al. The box-1 region of the leukemia inhibitory factor receptor alpha-chain cytoplasmic domain is sufficient for hemopoietic cell proliferation and differentiation. J Biol Chem 273 (1998) 34370-34383
27. Jazayeri J.A., De Weerd N., Raye W., Kivivuori S., Zabihi E., and Carroll G.J. In vitro evaluation of leukemia inhibitory factor receptor antagonists as candidate therapeutics for inflammatory arthritis. J Interferon Cytokine Res 27 (2007) 281-289
28. Dasgupta B., Corkill M., Kirkham B., Gibson T., and Panayi G. Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. J Rheumatol 19 (1992) 22-25
29. Heid C.A., Stevens J., Livak K.J., and Williams P.M. Real time quantitative PCR. Genome Res 6 (1996) 986-994
30. Chung C.D., Liao J., Lui B., Rao X., Jay P., Berta P., et al. Specific inhibiton of Stat3 signal transduction by PIAS3. Science 278 (1997) 1803-1805
31. Manolagas S.C. The role of IL-6 type cytokines and their receptors in bonea. Ann NY Acad Sci 840 (1998) 194-204
32. Cunnane G., Fitzgerald O., Beeton C., Cawston T.E., and Bresnihan B. Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis. Arthritis Rheum 44 (2001) 2263-2274
33. Ainola M.M., Mandelin J.A., Liljestrom M.P., Li T.F., Hukkanen M.V., and Konttinen Y.T. Pannus invasion and cartilage degradation in rheumatoid arthritis: involvement of MMP-3 and interleukin-1beta. Clin Exp Rheumatol 23 (2005) 644-650
34. Tchetverikov I., Ronday H.K., Van El B., Kiers G.H., Verzijl N., TeKoppele J.M., et al. MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis. Ann Rheum Dis 63 (2004) 881-883
35. Baker A.H., Edwards D.R., and Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 115 (2002) 3719-3727
36. Economides A.N., Carpenter L.R., Rudge J.S., Wong V., Koehler-Stec E.M., Hartnett C., et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nature Med 9 (2003) 47-52
37. Nagase H., Enghild J.J., and Suzuki K. G.S. Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and (4-aminophenyl)mercuric acetate. Biochemistry 19 (1990) 5783-5789
38. Martel-Pelletier J., McCollum R., Fujimoto N., Obata K., Cloutier J.M., and Pelletier J.P. Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis. Lab Invest 70 (1994) 807-815
39. Ji H., Pettit A., Ohmura K., Ortiz-Lopez A., Duchatelle V., Degott C., et al. Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J Exp Med 196 (2002) 77-85
40. Myers A., Lakey R., Cawston T.E., Kay L.J., and Walker D.J. Serum MMP-1 and TIMP-1 levels are increased in patients with psoriatic arthritis and their siblings. Rheumatology 43 (2004) 272-276
41. Varghese S., Yu K., and Canalis E. Leukemia inhibitory factor and oncostatin M stimulate collagenase-3 expression in osteoblasts. Am J Physiol Endocrinol Metab 276 (1999) E465-E471
42. Richards C.D., Shoyab M., Brown T.J., and Gauldie J. Selective regulation of metalloproteinase inhibitor (TIMP-1) by oncostatin M in fibroblasts in culture. J Immunol 150 (1993) 5596-5603
43. Otero M., and Goldring M.B. Cells of the synovium in rheumatoid arthritis. Chondrocytes. Arthritis Res Ther 9 (2007) 220
44. Nemoto O., Yamada H., Mukaida M., and Shimmei M. Stimulation of TIMP-1 production by oncostatin M in human articular cartilage. Arthritis Rheum 39 (1996) 560-566
45. Cawston T.E., Ellis A.J., Humm G., Lean E., Ward D., and Curry V. Interleukin-1 and oncostatin M in combination promote the release of collagen fragments from bovine nasal cartilage in culture. Biochem Biophys Res Commun 215 (1995) 377-385
46. Liand W.Q., and Zafarullah M. Oncostatin M up-regulates tissue inhibitor of metalloproteinases-3 gene expression in articular chondrocytes via de novo transcription, protein synthesis, and tyrosine kinase- and mitogen-activated protein kinase-dependent mechanisms. J Immunol 161 (1998) 5000-5007
47. Korzus E., Nagase H., Rydell R., and Travis J. The mitogen-activated protein kinase and JAK-STAT signaling pathways are required for an oncostatin M-responsive element-mediated activation of matrix metalloproteinase 1 gene expression. J Biol Chem 272 (1997) 1188-1196
48. Vernallis A.B., Hudson K.R., and Heath J.K. An antagonist for the leukemia inhibitory factor receptor inhibits leukemia inhibitory factor, cardiotrophin-1, ciliary neurotrophic factor, and oncostatin M. J Biol Chem 272 (1997) 26947-26952
49. Cawston T. Matrix metalloproteinases and TIMPs: properties and implications for the rheumatic diseases. Mol Med Today 4 (1998) 130-137